Preview complete
The prescreener preview is complete. You may now close the preview.
AI-powered
Key Adverse Events Following Childhood Cancer
Investigating Late Complications After Childhood Cancer Treatment
Recruiting
21 years or below
All
Phase
N/A
1 Location
Brief description of study.
The goal of this study is to identify subjects who are more likely to develop a late-occurring complication(s) after undergoing treatment for childhood cancer.
Detailed description of study
The purpose of this study is to identify key adverse events developing in patients (cases) with a primary cancer diagnosed at age 21 or younger.
Participants will not be paid for their participation.
Participants will not be paid for their participation.
Participants will not be paid for their participation.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: childhood cancer
-
Age: 21 years or below
-
Gender: All
Inclusion Criteria
Diagnosis of primary cancer at age 21 or younger
In active follow-up by a Children's Oncology Group (COG) institution
Development of one of the following key adverse events after initiation of prior cancer therapy:Cardiac dysfunction, Myocardial infarction, Ischemic stroke, Avascular necrosis, Subsequent malignant neoplasm
Exclusion Criteria
Prior allogeneic (non-autologous) hematopoietic cell transplant
Updated on
19 Feb 2024.
Study ID: 1011003233 (PHO-COG-FALLON-ALTE03N1)
This study investigates the occurrence of late complications in individuals who have undergone treatment for childhood cancer. Childhood cancer refers to cancer diagnosed in individuals aged 21 or younger. The study aims to identify key adverse events, which are unexpected medical issues that occur during or after treatment.
Participants will be monitored for specific health problems that may arise after their initial cancer therapy. These include heart problems, heart attacks, strokes, bone death, and new cancers. The study will help to understand how often these issues occur and who might be more at risk.
- Who can participate: Participants must have been diagnosed with primary cancer at age 21 or younger and be actively followed by a Children's Oncology Group institution. They must also have developed specific adverse events like cardiac dysfunction or ischemic stroke after starting cancer therapy. Those who have had a non-autologous hematopoietic cell transplant are excluded.
- Study details: Participants will be observed for the development of specific health conditions following their cancer treatment. These conditions include heart problems, strokes, and new cancers. No medication or placebo is involved in this study.
Pre-Screener
